It is important to note that Socinski et al. (2018) reported that Atezolizumab improved PFS and OS among patients with metastatic nonsquamous NSCLC, regardless of PD-L1 expression and EGFR or anaplastic lymphoma kinase (ALK) genetic alteration status. This evidence concerns the gene ALK and non-small cell lung carcinoma.